Use of carbamate compounds for the alleviation or treatment of developmental disorders, including fragile X syndrome, Angelman syndrome, or Rett syndrome

A carbamate compound is used to treat developmental disorders like Fragile X, Angelman, and Rett syndromes by targeting underlying symptoms, offering a more effective therapeutic approach than existing treatments.

JP7588675B2Active Publication Date: 2024-11-22SK BIOPHARMACEUTICALS CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023061122
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-11-14
Filing Date
2023-04-05
Publication Date
2024-11-22
Estimated Expiration
2038-11-13

AI Technical Summary

Technical Problem

Current treatments for developmental disorders such as Fragile X syndrome, Angelman syndrome, and Rett syndrome are limited to symptom management and lack fundamental therapeutic options.

Method used

The use of a therapeutically effective amount of a carbamate compound, or its pharmaceutically acceptable salt, solvate, or hydrate, to alleviate or treat these disorders, targeting developmental delays, learning disabilities, social behavior disorders, and seizures.

Benefits of technology

The carbamate compound effectively reduces symptoms of developmental disorders, including seizures and cognitive impairments, in preclinical models, demonstrating potential for therapeutic benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588675000014
    Figure 0007588675000014
  • Figure 0007588675000015
    Figure 0007588675000015
  • Figure 0007588675000016
    Figure 0007588675000016
Patent Text Reader

Abstract

To provide a medicine and a method for alleviating or treating developmental disorders.SOLUTION: The present invention relates to the use of a carbamate compound of formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for alleviating or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a compound represented by the following formula (1): [ka] (wherein R1, R2, A1 and R2 are as defined herein). or a pharma- ceutically acceptable salt, solvate or hydrate thereof for the alleviation or treatment of developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome. [Background technology]

[0002] Treatments for developmental disorders such as Fragile X syndrome (FXS), Rett syndrome, and Angelman syndrome are limited.

[0003] Fragile X syndrome (FXS) is a genetic disorder that is the most common monogenic cause of autism and is a genetic cause of intellectual disability, especially in boys. Fragile X syndrome is caused by a mutation in the fragile X mental retardation 1 (Fmr1) gene on the X chromosome. The Fmr1 gene was the first autism-associated gene to be identified and codes for the fragile X mental retardation protein (FMRP), an RNA-binding protein that regulates translation. Thus, the FMRP protein is made by the Fmr1 gene, which is necessary for normal brain development and is not made enough in fragile X syndrome (Non-Patent Document 1). This loss of function usually occurs when there is an expansion of a CGG trinucleotide repeat in the 5' non-station region of the Fmr1 gene. This expansion is manifested as a weak or "fragile-like" end of the X chromosome.

[0004] Fragile X syndrome occurs in both men and women, but symptoms in women are relatively milder than in men, and the incidence is higher in men than in women. According to another report, the disease occurs in one out of every 4,600 men and one out of every 8,000 women (Non-Patent Document 2).

[0005] Symptoms of fragile X syndrome include developmental delays, learning disabilities, and social behavior disorders (eye misalignment, anxiety, attention problems, tremors, speaking and acting without thinking, hyperactivity, etc.). Males have moderate to severe intellectual disabilities, and some females have normal categorical intelligence or some have intellectual disabilities. Autism spectrum disorder is commonly seen in individuals with fragile X syndrome (Non-Patent Document 1). In addition, fragile X syndrome is known to be at risk for seizures, with approximately 14% of males and 4% of females experiencing seizures (Non-Patent Document 3).

[0006] To diagnose fragile X syndrome, a blood DNA test is used to check for abnormalities in the FMR1 gene.

[0007] So far, there is no cure for FXS. Appropriate education can help, and medications may be used to reduce behavioral disorders and seizures.

[0008] Angelman syndrome is a condition that occurs when a specific gene on chromosome 15 is not inherited genetically. Symptoms of Angelman syndrome include developmental delay, intellectual disability, social and behavioral problems (excitability, hyperactivity, attention problems), and seizures.

[0009] Also, autism spectrum disorder frequently occurs in people with Angelman syndrome. To date, there is no fundamental treatment for Angelman syndrome. Appropriate education can help, and drugs may be used to alleviate the symptoms of Angelman syndrome described above.

[0010] Rett syndrome is a disease caused by a genetic mutation in the MECP2 gene. Symptoms of Rett syndrome include developmental delay, intellectual disability, social and behavioral disorders (excitable personality, hyperactivity, attention problems), and seizures.

[0011] Also, people with Rett syndrome show symptoms similar to autism spectrum disorder. To date, there is no cure for Rett syndrome. Appropriate education can help, and drugs may be used to alleviate the symptoms of Rett syndrome described above.

[0012] In other words, fragile X syndrome, Angelman syndrome, and Rett syndrome share common symptoms of developmental delay, intellectual disability, social behavior disorders, seizures, and autism spectrum disorder (or similar symptoms), and share the common feature that drugs are administered to alleviate symptoms because there is no cure for the underlying condition. [Prior art documents] [Non-patent literature]

[0013] [Non-Patent Document 1] Center for Disease Control and Prevention [Non-Patent Document 2] Genetics Home Reference, National Library of Medicine [Non-Patent Document 3] Berry-Kravis et al., 2010, “Seizures in Fragile X Syndrome: Characteristics and Comorbid Diagnoses,” Am J Intellect Dev Disabil. 115 (6): 461-72 Summary of the Invention [Problem to be solved by the invention]

[0014] The present invention aims to provide a method for alleviating or treating a developmental disorder.

[0015] The present invention also provides a therapeutically effective amount of a compound represented by the following formula (1): [ka] (wherein R1, R2, A1 and R2 are as defined herein). or a pharma- ceutically acceptable salt, solvate or hydrate thereof for use in alleviating or treating developmental disorders.

[0016] The present invention aims to provide a method for alleviating or treating fragile X syndrome.

[0017] Another object of the present invention is to provide use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for alleviating or treating fragile X syndrome.

[0018] It is a further object of the present invention to provide a method for alleviating or treating Angelman syndrome.

[0019] Another object of the present invention is to provide use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for alleviating or treating Angelman syndrome.

[0020] It is a further object of the present invention to provide a method for alleviating or treating Rett Syndrome.

[0021] Another object of the present invention is to provide use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for alleviating or treating Rett syndrome. [Means for solving the problem]

[0022] The present invention relates to a therapeutically effective amount of [ka] (Wherein, R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, haloC1-C8 alkyl, C1-C8 thioalkoxy, and C1-C8 alkoxy; one of A1 and A2 is CH and the other is N.) or a pharma- ceutical agent for alleviating or treating a developmental disorder, comprising a carbamate compound represented by the following formula (I):

[0023] The present invention also provides a method for alleviating or treating a developmental disorder in a subject, comprising administering to the subject a therapeutically effective amount of a carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof.

[0024] Furthermore, the present invention provides use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for the alleviation or treatment of a developmental disorder.

[0025] The present invention also provides a pharmaceutical for alleviating or treating fragile X syndrome, comprising a therapeutically effective amount of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof.

[0026] Furthermore, the present invention provides a method for alleviating or treating fragile X syndrome in a subject, comprising administering to the subject a therapeutically effective amount of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof.

[0027] The present invention also provides use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for alleviating or treating fragile X syndrome.

[0028] Furthermore, the present invention provides a pharmaceutical for alleviating or treating Angelman syndrome, comprising a therapeutically effective amount of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof.

[0029] The present invention also provides a method for alleviating or treating Angelman syndrome in a subject, comprising administering to the subject a therapeutically effective amount of a carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof.

[0030] The present invention further provides use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for the alleviation or treatment of Angelman syndrome.

[0031] The present invention also provides a pharmaceutical for alleviating or treating Rett syndrome, comprising a therapeutically effective amount of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof.

[0032] Furthermore, the present invention provides a method for alleviating or treating Rett syndrome in a subject, comprising administering to the subject a therapeutically effective amount of a carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof.

[0033] The present invention also provides use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for alleviating or treating Rett syndrome.

[0034] According to one embodiment of the present invention, in the formula (1), R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, and C1-C8 alkyl.

[0035] In one embodiment, the haloC1-C8 alkyl is perfluoroalkyl.

[0036] According to another embodiment of the present invention, the carbamate compound of formula (1) is represented by the following formula (2): [ka] The carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester is represented by the formula:

[0037] The carbamate compounds of formula (1) and (2) can be produced by a person having ordinary knowledge of compound synthesis in the art using known compounds or compounds that can be easily produced by using the known compounds. In particular, the method for producing the compound of formula (1) is described in detail in International Patent Publications WO2006 / 112685A1, WO2010 / 150946A1 and WO2011 / 046380A2, and the above documents are incorporated herein by reference. The compound of formula (1) can be chemically synthesized according to any of the methods described in the above documents, but these methods are merely examples, and the order of unit operations may be selectively changed as necessary. Therefore, it is not intended to limit the scope of the present invention.

[0038] The carbamate compounds of formula (1) can be used to alleviate or treat developmental disorders including fragile X syndrome, Angelman syndrome, or Rett syndrome.

[0039] The carbamate compounds of formula (1) can also be used to prevent, alleviate or treat symptoms of developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome.

[0040] Symptoms of developmental disorders include developmental delays, learning disabilities, social behavioural disorders (such as misalignment of eyes, anxiety, attention problems, trembling hands, talking or acting without thinking, hyperactivity) or seizures.

[0041] Symptoms of fragile X syndrome include developmental delays, learning disabilities, and social behavior disorders (eye misalignment, anxiety, attention problems, tremors, speaking and acting without thinking, hyperactivity, etc.). Males have moderate to severe intellectual disabilities, and some females have normal categorical intelligence or some have intellectual disabilities. Autism spectrum disorder is commonly seen in individuals with fragile X syndrome (Non-Patent Document 1). In addition, fragile X syndrome is known to be at risk for seizures, with approximately 14% of males and 4% of females experiencing seizures (Non-Patent Document 3).

[0042] Symptoms of Angelman syndrome and Rett syndrome include developmental delay, intellectual disability, social and behavioral problems (excitability, hyperactivity, attention problems), and seizures.

[0043] Thus, the medicaments and pharmaceutical compositions of the present invention can be used to prevent, alleviate or treat symptoms of developmental disorders including Fragile X Syndrome, Angelman Syndrome or Rett Syndrome, including, but not limited to, developmental delays, learning disabilities, social behavioral disorders and seizures.

[0044] In addition, the pharmaceutical composition of the present invention is useful for treating autism spectrum disorders caused by fragile X syndrome, Angelman syndrome, and Rett syndrome. Ram Disorders, or autism spectrum disorders with symptoms similar to those of Fragile X syndrome, Angelman syndrome, and Rett syndrome Ram It can be used to alleviate or treat disorders.

[0045] The efficacy of the compound of formula (1) for developmental disorders including fragile X syndrome, Angelman syndrome, or Rett syndrome can be confirmed by using known models. For example, Fmr1 gene-deficient mouse models express some clinical symptoms observed in developmental disorders such as fragile X syndrome, Angelman syndrome, or Rett syndrome, and are used as a means of verifying drug efficacy for studying disease mechanisms and developing treatments (Bakker et al., 1994, "Fmr1 knockout mice: A model to study fragile X mental retardation", Cell, 15; 78 (1): 23-33). Typical phenotypes of this mouse model include auditory seizures, hyperactivity, cognitive dysfunction, and attention problems.

[0046] The dosage of the carbamate compound of formula (1) for the alleviation or treatment of the disease usually varies depending on the severity of the disease, the body weight and metabolic state of the subject to be treated. The "therapeutically effective amount" for an individual patient means an amount of the active compound sufficient to achieve the pharmacological effect, i.e., the therapeutic effect. The therapeutically effective amount of the compound of formula (1) is 50-500 mg, 50-400 mg, 50-300 mg, 100-400 mg, 100-300 mg, 50-200 mg, or 100-200 mg, based on a single daily administration of the free form, when administered to humans.

[0047] The compounds of the present invention can be administered by any conventional method used for administering therapeutic agents, including oral, parenteral, intravenous, intramuscular, subcutaneous or rectal administration.

[0048] A medicament or pharmaceutical composition according to one embodiment of the present invention can comprise a therapeutically effective amount of a compound selected from the group consisting of the carbamate compounds of the present invention, their pharma- ceutically acceptable salts, solvates, hydrates, and combinations thereof.

[0049] Pharmaceutically acceptable salts of the carbamate compounds of formula (1) include, for example, independently, acetate, benzenesulfonate, benzoate, bitartrate, calcium acetate, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogencarbonate, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl nitrate, methyl methacrylate ... These include ethylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate or hemi-succinate, sulfate or hemi-sulfate, tannate, tartrate, oxalate or hemi-tartrate, theoclate, triethiodide, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, ammonium, tetramethylammonium, calcium, lithium, magnesium, potassium, sodium and zinc.

[0050] The medicament or pharmaceutical composition according to one embodiment of the present invention can be administered orally or parenterally. Parenteral administration can be by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intravaginal administration, pulmonary administration, and rectal administration, etc. For oral administration, the pharmaceutical composition according to one embodiment can be formulated as a plain tablet (uncoated tablet) or such that the active agent is coated or protected from digestion in the stomach. The composition can also be administered by any device that allows the active agent to be transferred to the target cells. The route of administration will vary depending on the general condition and age of the subject to be treated, the nature of the condition to be treated, and the active ingredient selected.

[0051] The suitable dosage of the medicament or pharmaceutical composition according to one embodiment of the present invention varies depending on factors such as the formulation method, administration method, age, weight, sex, pathological condition, diet, administration time, administration route, excretion rate and reaction sensitivity of the patient, and a doctor of ordinary skill can easily determine and prescribe an effective dosage for the desired treatment or prevention. The pharmaceutical composition according to one embodiment can be administered in one or more doses, for example, 1 to 4 times per day. The pharmaceutical composition according to one embodiment contains the compound of formula (1) in a free form of 50 to 500 mg, 50 to 400 mg, 50 to 300 mg, 100 to 400 mg, 100 to 300 mg, 50 to 200 mg, or 100 to 200 mg.

[0052] The medicament or pharmaceutical composition according to one embodiment of the present invention can be prepared in unit dose form or in a multi-dose container by formulating it using pharma- ceutically acceptable carriers and / or excipients according to a method that can be easily performed by a person skilled in the art. The formulation may be in the form of a solution, suspension or emulsion in an oily or aqueous medium, an extract, a powder, a granule, a tablet or a capsule, and may additionally contain a dispersing agent or a stabilizing agent. The pharmaceutical composition may also be administered in the form of a suppository, a spray, an ointment, a cream, a gel, an inhalant or a skin patch. The pharmaceutical composition may also be prepared for mammalian administration, more preferably for human administration.

[0053] The pharma- ceutically acceptable carrier may be solid or liquid, and may be one or more selected from excipients, antioxidants, buffers, bacteriostatic agents, dispersants, adsorbents, surfactants, binders, preservatives, disintegrants, sweeteners, flavorings, lubricants, release regulators, wetting agents, stabilizers, suspending agents, and lubricants.Furthermore, the pharma-ceutically acceptable carrier may be selected from physiological saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures thereof.

[0054] In one embodiment, suitable fillers include, but are not limited to, sugars (e.g., dextrose, sucrose, maltose, and lactose), starches (e.g., corn starch), sugar alcohols (e.g., mannitol, sorbitol, maltitol, erythritol, and xylitol), starch hydrolysates (e.g., dextrins and maltodextrins), cellulose or cellulose derivatives (e.g., microcrystalline cellulose), or mixtures thereof.

[0055] In one embodiment, suitable binders include, but are not limited to, povidone, copovidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, gums, sucrose, starch, or mixtures thereof.

[0056] In one embodiment, suitable preservatives include, but are not limited to, benzoic acid, sodium benzoate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, gallate, hydroxybenzoate, EDTA, or mixtures thereof.

[0057] In one embodiment, suitable disintegrants include, but are not limited to, sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starch, microcrystalline cellulose, or mixtures thereof.

[0058] In one embodiment, suitable sweetening agents include, but are not limited to, sucralose, saccharin, sodium or potassium or calcium saccharin, acesulfame potassium or sodium cyclamate, mannitol, fructose, sucrose, maltose, or mixtures thereof.

[0059] In one embodiment, suitable lubricants include, but are not limited to, silica, colloidal silicone dioxide, talc, and the like.

[0060] In one embodiment, suitable lubricants include, but are not limited to, long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glyceride waxes, or mixtures thereof.

[0061] As used herein, the terms "prevent," "preventing," and "prevention" refer to reducing or eliminating the chance of acquiring a disease.

[0062] As used herein, the terms "ameliorate," "alleviating," and "alleviation" refer to the complete or partial alleviation of a disease and / or its associated symptoms.

[0063] As used herein, the terms "treat", "treating" and "treatment" refer to the total or partial elimination of a disease and / or its associated symptoms.

[0064] The term "subject" as used herein means an animal, preferably a mammal (e.g., primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc.), most preferably a human, who is the subject of treatment, observation or experiment.

[0065] As used herein, the term "therapeutically effective amount" refers to an amount of an active compound or pharmaceutical formulation that induces a biological or medical response in a system, animal or human, including alleviating the symptoms of the disease or disorder being treated, as determined by a researcher, veterinarian, physician or other clinician.

[0066] As used herein, the term "composition" includes a product containing the specified ingredients in the specified amounts, and any product produced directly or indirectly from the combination of the specified ingredients in the specified amounts. Further aspects of the invention are described below: [Section 1] A therapeutically effective amount of

change

change

change

change

[0067] The medicaments and pharmaceutical compositions according to the present invention can effectively alleviate and treat developmental disorders such as fragile X syndrome, Angelman syndrome or Rett syndrome. [Brief description of the drawings]

[0068] [Figure 1] In an audiogenic seizure test conducted using an Fmr1 gene-deficient mouse model, the results show the inhibitory effect of the test compounds (10 mg / kg, 20 mg / kg) and the positive control group MPEP (2-methyl-6-(phenylethynyl)pyridine) on the occurrence of seizures. [Diagram 2] In an auditory seizure test performed using an Fmr1 gene-deficient mouse model, the test compounds (10 mg / kg, 20 mg / kg) and the positive control group MPEP showed a preventive effect on respiratory arrest due to seizures. [Diagram 3] The results show the effect of the test compounds (10 mg / kg, 20 mg / kg) and the positive control group MPEP on modulating seizure intensity in an auditory seizure test performed using an Fmr1 gene-deficient mouse model. [Figure 4] 1 shows the effect of test compounds (10 mg / kg, 20 mg / kg) and the positive control group MPEP on mouse survival rate in an auditory seizure test performed using an Fmr1 gene-deficient mouse model. [Diagram 5] 1 shows the effect of test compounds (10 mg / kg, 20 mg / kg) and the positive control group MPEP on the incidence of seizures in mice in an auditory seizure test conducted using an Fmr1 gene-deficient mouse model. [Figure 6] 1 shows the effect of a test compound (10 mg / kg, 20 mg / kg) on ​​locomotor activity in an Fmr1 gene-deficient mouse model. [Figure 7] 1 shows the effect of test compounds (10 mg / kg, 20 mg / kg) on ​​increased rearing activity in an Fmr1 gene-deficient mouse model. [Figure 8] The results show that in a contextual fear conditioning experiment using an Fmr1 gene-deficient mouse model, the test compound (10 mg / kg, 20 mg / kg) had a reduced effect on fear conditioning. [Figure 9] The results show that in a cued fear conditioning experiment using an Fmr1 gene knockout mouse model, the test compound (10 mg / kg, 20 mg / kg) had a reduced effect on fear conditioning. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0069] The present invention will now be described in further detail with reference to the following examples, which are intended, however, only to illustrate one or more embodiments and are not intended to limit the scope of the invention. EXAMPLES

[0070] Production Example: Production of carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester Carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester (test compound) was prepared according to the method described in Preparation 50 of International Publication No. WO2010 / 150946.

[0071] Example 1: Anticonvulsant efficacy test against audiogenic seizures in FMR1 gene-deficient mouse model The Fmr1 knockout mouse model lacks FMRP protein due to the disruption of the Fmr1 gene, and the typical phenotype of this mouse is auditory seizures, hyperactivity, cognitive deficit, and attention disorder. Thus, the Fmr1 knockout mouse model shows some clinical symptoms observed in developmental disorders such as fragile X syndrome, Angelman syndrome, and Rett syndrome, and is used as a means to study the mechanism of developmental disorders and to verify the efficacy of drugs for the development of therapeutic agents (Kazdoba et al., 2014, “Modeling fragile X syndrome in the Fmr1 knockout mouse”, Intractable Rare Dis Res. 2014 Nov; 3(4): 118-133; Bakker et al., 1994, “Fmr1 knockout mice: A model to study fragile X mental retardation”, Cell, 15; 78(1): 23-33).

[0072] Experimental animals Male FVB.129P2-Pde6b+ Tyrc-ch Fmr1tm1Cgr / J gene-deficient mice were obtained from Jackson Laboratories and subjected to auditory seizure experiments at 3 weeks of age. After obtaining the animals, they were raised under a controlled lighting environment (12 hours light / 12 hours dark) and maintained at a temperature of 20-23°C and a relative humidity of approximately 50%. Food and water were provided ad libitum. Mice were randomly divided into groups. The experiments were performed under light.

[0073] Drugs As a positive control, MPEP (2-methyl-6-(phenylethynyl)pyridine) HCl was used, dissolved in sterile saline for injection and administered intraperitoneally at a dose of 30 mg / kg. MPEP was prepared in a volume of 10 mL / kg and administered 30 minutes before the test.

[0074] The test compound was dissolved in 30% PEG300 and used at two doses of 10 mg / kg and 20 mg / kg. The compound was prepared in a volume of 10 mL / kg and administered intraperitoneally 30 minutes before the test. As a negative control group, the vehicle (30% PEG300) was administered.

[0075] Study Group 1. Fmr1 knockout mice - vehicle administration 2. Fmr1 knockout mice - MPEP 30mg / kg administration 3. Fmr1 gene-deficient mice - 10 mg / kg test compound administered 4. Fmr1 gene-deficient mice - 20 mg / kg test compound administered Ten mice were used per group.

[0076] Auditory seizure testing Vehicle, MPEP or test compound was administered to 21-day-old mice 30 minutes prior to testing. Mice were placed in a Plexiglas chamber for 15 seconds and exposed to a 135 decibel (dB) sound. During the 5-minute test, mice were scored according to the following criteria based on their response, the time required to respond, and the intensity of the seizure: 0: No response 1. Wild running and jumping 2: Clonic seizures 3: Tonic-clonic seizures 4: Tonic seizures 5: Stop breathing

[0077] The following endpoints were measured and observed, and in non-responsive animals, the latency to response was set at 300 seconds for convenience of analysis. 1. Time to seizure onset (300 seconds if no seizure occurs) 2. Time to respiratory arrest (300 seconds if alive without respiratory arrest) 3. Seizure Intensity 4.Survival rate 5. Seizure incidence

[0078] statistical analysis Data were analyzed by analysis of variance, with Fisher PLSD post-hoc analysis where appropriate. Mean seizure intensity was analyzed nonparametrically. Effects were defined as significant if p<0.05. Results are expressed as mean ± SEM.

[0079] Test results 1. Weight Body weights measured before administration on the day of the study were analyzed by one-way analysis of variance, and no significant differences were found between groups.

[0080] 2. Time to seizure onset The time required for seizure onset was significantly increased in the groups treated with MPEP (30 mg / kg) and test compound (10, 20 mg / kg) compared to the vehicle-treated group. Mice treated with MPEP and test compound did not develop seizures, and the time required for seizure onset was recorded as 300 seconds (Figure 1).

[0081] 3. Time to respiratory arrest The groups treated with MPEP (30 mg / kg) and test compound (10, 20 mg / kg) showed a significant increase in the time required for respiratory arrest compared to the vehicle-treated group. The mice treated with MPEP and test compound did not undergo respiratory arrest, and the time required for respiratory arrest was recorded as 300 seconds (Figure 2).

[0082] 4. Average Seizure Intensity The groups administered MPEP (30 mg / kg) and the test compound (10, 20 mg / kg) showed a significant reduction in the numerical seizure intensity in mice compared to the vehicle-administered group (FIG. 3).

[0083] 5.Survival rate The survival rate of mice in the groups administered MPEP (30 mg / kg) and the test compound (10, 20 mg / kg) was significantly increased compared to the vehicle-administered group, with a survival rate of 100% (Figure 4).

[0084] 6. Seizure incidence In the groups administered MPEP (30 mg / kg) and the test compound (10, 20 mg / kg), no seizures occurred at all (FIG. 5).

[0085] Example 2: Open field test and fear conditioning test in FMR1 gene-deficient mouse model Experimental animals Male FVB.129P2-Pde6b+ Tyrc-ch Fmr1tm1Cgr / J gene-deficient mice were obtained from Jackson Laboratories and were maintained under a controlled lighting environment (12 hours light / 12 hours dark) at 20-23°C and approximately 50% relative humidity. Food and water were provided ad libitum. Mice were randomly assigned to groups. Drugs were administered once daily for 6 days at 8 weeks of age. The study was performed under light.

[0086] Drugs The test compound was dissolved in 30% PEG300 and used at two doses of 10 mg / kg and 20 mg / kg. The test compound was prepared in a volume of 10 mL / kg and administered intraperitoneally 30 minutes before the test.

[0087] Study Group 1. Wild-type mice - vehicle administration 2. Fmr1 gene-deficient mice - vehicle 3. Fmr1 gene-deficient mice - test compound 10 mg / kg 4. Fmr1 gene-deficient mice - test compound 20mg / kg Ten mice were used per group.

[0088] Open field test and fear conditioning test 1. Locomotor activity: Eight-week-old mice were administered the drug once a day for six days, and activity tests were performed on the fourth day of administration.

[0089] Horizontal and vertical movement were measured using a square Plexiglas chamber (27.3 × 27.3 × 20.3 cm) surrounded by infrared light. Mice were allowed to habituate to the experimental room for at least 1 h before testing, and then placed in the center of the chamber and activity in the open field was measured for 1 h. The test run space was cleaned after each change of mouse. Distance traveled was measured by the interruption of a horizontal light beam by mouse movement. Time-dependent changes in activity and rearing activity (hind rearing) were expressed in 5-min increments. Total distance traveled and total number of rearing were summed over a 60-min period.

[0090] 2. Fear conditioning test: On the fifth and sixth days after administration, training and a drug efficacy confirmation test were carried out 30 minutes after administration. The tests were carried out using a fear conditioning system manufactured by Coulbourn Instruments (PA, USA).

[0091] Training was performed 30 minutes after administration on the fifth day of administration. Mice were placed in the conditioning chamber, allowed to acclimate to the environment for 120 seconds, and exposed to a 6 kHz, 75 dB sound stimulus (conditioned stimulus) for 20 seconds. Thirty seconds after the end of the conditioned stimulus, a 0.5 mA electric shock (non-conditioned stimulus) was administered to the mouse foot. The mice were placed in the conditioning chamber for an additional 60 seconds, after which they were returned to their original cages.

[0092] On the morning of the 6th day, 30 min after administration, mice were placed in the same chamber as the previous day and trained for 5 min without shock or other obstacles to conduct a drug efficacy test on environmental memory. On the afternoon of the 6th day, 4 h after the environmental conditioning test, a drug efficacy test on cued memory was conducted. Mice were exposed to a new environment for 2 min (before the stimulus signal), and the conditioning and stimulus were added for 20 s, a total of three times. Freezing behavior was defined as a complete loss of movement and was captured using a video system and Freeze View software (Coulbourn Instruments, PA, USA). The chamber was washed with 70% ethanol every time mice were replaced.

[0093] statistical analysis Data were analyzed by ANOVA followed, where appropriate, by Fisher PLSD post-hoc analysis using Stat view software. Effects were defined as significant when p<0.05. Results are expressed as mean ± SEM.

[0094] Open field test results 1.Locomotor activity The change in activity over a 60-minute period is shown in Figure 6A, and the total distance traveled is shown in Figure 6B. ANOVA analysis showed that Fmr1 gene-deficient mice administered with the vehicle showed significantly increased activity compared to wild-type mice. In addition, activity was significantly decreased in the Fmr1 gene-deficient mice administered with 20 mg / kg of the test compound compared to the vehicle-administered group.

[0095] 2. Rearing The time course of rearing frequency over a 60-minute period is shown in FIG. 7A, and the number of rearing episodes is shown in FIG. 7B. ANOVA analysis showed that the number of rearing episodes was increased in Fmr1 gene-deficient mice treated with vehicle compared to wild-type mice, but this was not significant. In addition, the number of rearing episodes was decreased in Fmr1 gene-deficient mice treated with 20 mg / kg of the test compound compared to the vehicle group.

[0096] Fear conditioning test results 1.Contextual fear conditioning The freezing rate during the environmental fear conditioning test is shown in Figure 8. ANOVA analysis showed that the Fmr1 gene-deficient mice administered with the vehicle showed significantly reduced freezing compared to wild-type mice. Furthermore, the Fmr1 gene-deficient mice showed significantly increased freezing in the test compound 10 mg / kg and 20 mg / kg groups compared to the vehicle group, and showed freezing similar to the wild-type mice.

[0097] 2. Cue test Figure 9 shows the fear conditioning by the stimulus signal and the behavioral arrest rate during the test. When all groups were analyzed, there was no significant difference between wild-type mice and Fmr1 gene-deficient mice. However, t-test showed a significant difference between wild-type mice and Fmr1 gene-deficient mice. For Fmr1 gene-deficient mice, one-way ANOVA was performed to compare the vehicle-administered group and the test compound-administered group. When comparing the time of giving the stimulus signal with the time after the stimulus signal, there was a significant administration effect on the behavioral arrest rate. During the presentation of the stimulus signal, the test compound significantly increased the behavioral arrest rate of Fmr1 gene-deficient mice at two doses. After the stimulus signal, there was a significant increase in behavioral arrest at a dose of 20 mg / kg of the test compound.

Claims

1. A therapeutically effective amount of the following formula (1) 【Chemistry 1】 (In the formula, R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 Alkyl, haloC 1 -C 8 Alkyl, C 1 -C 8 Thioalkoxy and C 1 -C 8 alkoxy; A 1 and A 2 One of them is CH and the other is N.) or a pharma- ceutical acceptable salt, solvate or hydrate thereof, wherein the autism spectrum disorder does not include autism spectrum disorder caused by fragile X syndrome.

2. The carbamate compound of formula (1) is represented by the following formula (2): 【Chemistry 2】 The pharmaceutical composition according to claim 1, characterized in that it is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester represented by the formula:

3. The method according to claim 1 or 2, characterized in that the therapeutically effective amount of the carbamate compound of formula (1) is 50 to 500 mg, based on a once-daily administration of the free form.

Citation Information

Patent Citations

  • Neurotherapeutic azole compounds

    JP2008538557A

  • JPP7258902B